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Genentech's original GMP production facility in South San Francisco, California, was approved by 
the FDA in 1985 and today is licensed to manufacture 10 marketed products. This legacy 
manufacturing plant has evolved over the years to become a complex multi-product facility that 
supplies both clinical and commercial products utilizing a 96,000 liter-capacity on the CHO line. 
The site’s flexibility along with proximal location of key functional areas including Operations, 
Process Development, Quality and Regulatory well position it as a launch site for new molecules. 
Balancing flexibility with older qualified equipment presents unique opportunities when launching 
new molecules in an aging multi-product facility. Some constraints include equipment resource 
overlap between clinical and commercial, reliance on single probes on bioreactors, ensuring 
adequate raw material inventory across multiple products and providing heightened process 
monitoring support with legacy automation systems. This poster will discuss the above challenges 
encountered and mitigation measures adopted during a recent new molecule licensure campaign 
at the Genentech South San Francisco Manufacturing facility.  
 
 
 
